Evaluation of CEA, CA19-9 and SPan-1 as tumor markers for colorectal cancer.

DOI Web Site Open Access
  • Togo K
    First Department of Surgery, Osaka City University Medical School
  • Okuno M
    First Department of Surgery, Osaka City University Medical School
  • Chung YS
    First Department of Surgery, Osaka City University Medical School
  • Ikehara T
    First Department of Surgery, Osaka City University Medical School
  • Nagayama M
    First Department of Surgery, Osaka City University Medical School
  • Nishimori T
    First Department of Surgery, Osaka City University Medical School
  • Kawaguchi M
    First Department of Surgery, Osaka City University Medical School
  • Yariyama H
    First Department of Surgery, Osaka City University Medical School
  • Umeyama K
    First Department of Surgery, Osaka City University Medical School

Bibliographic Information

Other Title
  • 大腸癌における腫ようマーカーの検討　とくにＣＥＡ，ＣＡ１９‐９，ＳＰａｎ‐１について
  • とくに CEA, CA19-9, SPan-1について

Search this article

Description

The clinical evaluations of serum CEA, CA19-9 and SPan-1 levels were studied in 109 patients with colorectal cancers. Positive rates of CEA, CA19-9 and SPan-1 were 40.4 %, 23.9% and 25.7% respectively. Positive rates of CEA in stage II III and IV were almost similar. Positive rates of CA19-9 rose in accordance with advanced histological stages. A positive rate of Span-1 was 25% in stage I, higher than those of CEA and CA19-9 in stage I, and positive rates of SPan-1 in stage IV and V were higher than in stage I, II and II. While a positive rate of CEA was only 40.4%, a combination assay of CEA and CA19-9 or SPan-1 increased to a positive rate of 51.4% or 55.6%. The most sensitive tumor marker in colorectal cancer was CEA. And moreover, a combination assay o CEA and CA19-9 or SPan-1 was considered to be useful for the serum diagnosis of colorectal cancer.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top